Meeting Banner
Abstract #1113

Radiomic Analysis Differentiates between True Progression and Pseudo-progression in Glioblastoma patients: A Large Scale Multi-institutional Study

Aikaterini Kotrotsou1, Srishti Abrol1, Nabil A Elshafeey1, Islam Hassan1, Dunia Giniebra Camejo2, Ahmed Hassan1, Tagwa Idris1, Ahmed Salem1, Kamel El Salek1, Ahmed Elakkad1, Kristin D Alfaro-Munoz3, Shiao-Pei Weathers3, Fanny E Moron4, John F deGroot3, Meng Law5, Pascal O Zinn6, and Rivka R Colen1,2

1Diagnostic Radiology, MD Anderson Cancer Center, Houston, TX, United States, 2Cancer Systems Imaging, MD Anderson Cancer Center, Houston, TX, United States, 3Neuro-Oncology, MD Anderson Cancer Center, Houston, TX, United States, 4Neuroradiology, Baylor College of Medicine, Houston, TX, United States, 5Neuroradiology, University of Southern California Keck Medical Center, Los Angeles, CA, United States, 6Neurosurgery, Baylor College of Medicine, Houston, TX, United States

The benign treatment-related imaging changes may pose a challenge in appropriate clinical decision making for the neuro-oncologists. The post-treatment changes are usually benign and differ largely in management approach from a progressive tumor. In this study, 304 glioblastoma patients were evaluated retrospectively to study the ability of radiomic analysis to distinguish the post-treatment changes from a truly progressive disease. 3D volumetrics using 3D Slicer 4.3.1 and texture analysis of the lesions were performed. On LOOCV, sensitivity and specificity of 97% and 72% were obtained respectively. We concluded that radiomics can differentiate between the progressive disease and pseudo-progression in glioblastoma patients.

This abstract and the presentation materials are available to members only; a login is required.

Join Here